Ikarian Capital’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-102,211
| Closed | -$758K | – | 176 |
|
|
2026
Q1 | $758K | Hold |
102,211
| – | – | 0.06% | 115 |
|
|
2025
Q4 | $643K | Sell |
102,211
-4,690
| -4% | -$27.4K | 0.05% | 134 |
|
|
2025
Q3 | $417K | Hold |
106,901
| – | – | 0.04% | 142 |
|
|
2025
Q2 | $490K | Hold |
106,901
| – | – | 0.09% | 91 |
|
|
2025
Q1 | $522K | Hold |
106,901
| – | – | 0.06% | 115 |
|
|
2024
Q4 | $718K | Buy |
106,901
+2
| +0% | +$15 | 0.1% | 120 |
|
|
2024
Q3 | $827K | Buy |
106,899
+20,000
| +23% | +$121K | 0.12% | 104 |
|
|
2024
Q2 | $521K | Hold |
86,899
| – | – | 0.09% | 94 |
|
|
2024
Q1 | $783K | Buy |
86,899
+1,560
| +2% | +$14.2K | 0.09% | 110 |
|
|
2023
Q4 | $809K | Hold |
85,339
| – | – | 0.08% | 105 |
|
|
2023
Q3 | $1.02M | Buy |
85,339
+1,179
| +1% | +$20.9K | 0.12% | 99 |
|
|
2023
Q2 | $2.06M | Hold |
84,160
| – | – | 0.33% | 64 |
|
|
2023
Q1 | $2.63M | Buy |
84,160
+21,161
| +34% | +$1.22M | 0.6% | 51 |
|
|
2022
Q4 | $4.44M | Sell |
62,999
-9,860
| -14% | -$731K | 1.07% | 31 |
|
|
2022
Q3 | $6.27M | Sell |
72,859
-67,953
| -48% | -$6.6M | 1.25% | 28 |
|
|
2022
Q2 | $11.6M | Buy |
140,812
+32,500
| +30% | +$2.87M | 2.12% | 14 |
|
|
2022
Q1 | $18M | Buy |
108,312
+6,220
| +6% | +$893K | 2.37% | 12 |
|
|
2021
Q4 | $17.1M | Buy |
+102,092
| New | +$11.5M | 2.54% | 8 |
|
Ikarian Capital's KZR Position: Q2 2026 in Review
Ikarian Capital sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 102,211 shares — an estimated $758K sold.
Ikarian Capital first reported a position in KZR in Q4 2021 and held it in 18 quarters. The position peaked at $18M in Q1 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Ikarian Capital reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Ikarian Capital sold 102,211 Kezar Life Sciences shares in Q2 2026, an estimated $758K.
- Ikarian Capital first reported a position in Kezar Life Sciences in Q4 2021 and held it in 18 quarters.
- Ikarian Capital's Kezar Life Sciences position peaked at $18M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.